A Hackensack Meridian Medical Center, New Jersey, research team has found that oxycloquine, which has been shown to be effective in certain patients with CCHV, may help reduce hospital admissions in mildly ill and early-stage patients.
In a recent study published in the peer-reviewed journal BMC Infectious Diseases, a team at Hackensack Meridian health in New Jersey found that hydroxychloroquine (abbreviated. HCQ) was shown to be effective in certain patients with CCLV (COVID-19, Neocoronavirus), and it may help reduce hospital admissions in mildly ill and early-stage patients.
Data show low hospitalization rates in patients taking hydroxychloroquine
Last spring and summer, Dr. Andrew Ip, who works at Hackensack Meridian Medical Center’s John Theurer Cancer Center, and his colleagues were looking for ways to treat patients with early-stage CCHV.
They had considered a number of different drugs, including blood thinners, steroids and immunosuppressants, and conducted a retrospective study looking at data the hospital had compiled from March through mid-May, including more than 1,200 outpatients who had contracted the CCP virus but had mild symptoms. Nearly one hundred of these outpatients were treated with hydroxychloroquine.
To the researchers’ surprise, only 1 in 5 of the patients treated with hydroxychloroquine required further hospitalization. In contrast, 1/3 of the patients who did not receive hydroxychloroquine required hospitalization. Dr. Yeh and his colleagues believe that this result is significant.
Repeated changes in FDA evaluation of hydroxychloroquine
Since the outbreak of the CCP virus, medical professionals have done everything possible to help early-stage patients. However, the report notes that there is no treatment endorsed by the World Health Organization or the Infectious Diseases Society of America that can be applied to outpatient treatment of early-stage patients.
In fact hydroxychloroquine was developed and studied early in the CCP virus crisis. On March 28 of last year, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for hydroxychloroquine and chloroquine. But in April it issued another warning about the use of hydroxychloroquine, saying that studies had shown the drug could cause side effects in some patients, including blurred vision, skin rashes, nausea and dizziness.
In June, the FDA went on to revoke emergency use authorization for hydroxychloroquine, saying it found that hydroxychloroquine and chloroquine “have not shown a benefit in reducing the likelihood of death or speeding recovery. The following month, the FDA issued “reports of serious heart rhythm problems and other safety issues associated with the drug, including blood and lymphatic system disorders, kidney damage and liver problems and failures,” among others.
But in the same month a study claiming that the drug caused higher mortality was also withdrawn.
International medical journals, including The Lancet, have published articles saying that “studies and trials” of the drug were insufficient to prove its effectiveness, limiting its availability on the market for a Time.
But in early July, a new study showed that hydroxychloroquine can reduce mortality in patients with the Chinese communist virus.
Researchers at Henry Ford Health System in Michigan analyzed the records of more than 2,500 patients and found that 13 percent of those treated with hydroxychloroquine died, compared with 26.4 percent of those who received only standard care, according to the English-language Epoch Times.
Frontline doctors: Hydroxychloroquine is the most effective anti-drug
Former White House adviser Peter Navarro said in July last year that India had concluded that taking oxycodone was effective and that early treatment with oxycodone in the U.S. could reduce the death rate of patients with the C.C.V. by 50 percent.
Last July 28, nearly two dozen doctors from America’s Frontline Doctors flew from various states to Washington, D.C., to hold a press conference in front of Capitol Hill to tell the world what they were doing on the front lines to save patients. The press conference was held in front of Capitol Hill to release the first-hand information they have obtained on the front lines: hydroxychloroquine is currently the most effective drug against the Chinese Communist virus.
The doctors said that the information and so-called “research data” on the CCP virus published by the mainstream media, the scientific community, and even the U.S. Department of Health Research (NIH) for months was untrue, incomplete, and seriously misleading, and that it was a politically motivated “massive, false data This is a “massive, false data propaganda campaign” with a political agenda.
The civil press conference was simulcast on Facebook for eight hours and received more than 17 million views, but the video was quickly removed and blocked by Facebook, Twitter and Google‘s YouTube.
Hydroxychloroquine’s role politicized
Former President Trump (Trump) was treated with hydroxychloroquine last year after he was confirmed to have contracted the Chinese Communist virus. Trump, who later recovered quickly, strongly recommended hydroxychloroquine to the public, hailing it as a potential miracle treatment against COVID-19, although Trump’s own doctors did not recommend its use.
Unfortunately, the incident was clearly politicized after Trump strongly recommended hydroxychloroquine.
“Dr. Simone Gold, a physician and attorney and founder of Frontline Doctors of America, said that simply focusing on the number of people infected doesn’t tell us much, but rather the number of hospital admissions and mortality rates is the issue.
Gold said frontline doctors’ experience shows that patients can be treated better by taking hydroxychloroquine twice a week and zinc daily. He said politicians have “politicized” the treatment of oxycodone, killing more than 100,000 Americans who could have been cured.
James Todaro, M.D., was the first doctor to publish an article on the ability of oxycodone to treat the Chinese Communist virus. He was also one of the early doctors to discover the fraudulent data published in The Lancet and to investigate it. Because of the false “scientific” data, several international organizations, including the European Union, halted research on hydroxychloroquine for a time.
Stella Immanuel, a doctor who spoke with emotion, said she had cured 350 patients with oxycodone or zinc. “They all recovered after taking hydroxychloroquine, and there was not a single death.”
No arrhythmia side effects found Study to expand sample group
Despite claims by federal health officials that hydroxychloroquine does not help hospitalized patients, Dr. Yeh and his team continued to sift through data from a group of outpatients treated with the drug last year. They found that this group of “mildly symptomatic” patients had reduced hospitalization rates.
They analyzed and studied the data again in June and July, at a time when everyone was saying that hydroxychloroquine wasn’t working, or that it didn’t seem to be doing much good.
The group receiving the drug included 57 whites, 6 African-Americans, 15 Latinos and 1 Asian.
Dr. Stephanie Silvera, an epidemiologist at Montclair State University, believes the study was “well designed and well analyzed. She expressed interest in seeing further research that would break down the limitations of existing studies, such as the lack of diversity in the population being studied. Nevertheless, she believes this study is a useful addition to the existing drug literature and deserves further study.
Dr. Ye also agreed that the study results have limitations due to the small sample size. He said the study was not conclusive in endorsing the drug, but was only a very small study from a handful of New Jersey hospitals. But they found a correlation that showed the drug improved access to care for patients at Hackensack Hospital.
The researchers also found no reports of arrhythmias in their sample of outpatients as claimed by the FDA as a result of taking the drug.
Dr. Yeh said the data are not controversial and are not scientifically disputed. The only thing that is controversial is that the drug has become something of a political symbol. He noted that it took some time and met with resistance to even get the data their team had studied published.
Recent Comments